image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Eric W. Joseph, Ph.D.
J.P. Morgan
Zhiqiang Shu, Ph.D.
Berenberg Capital Markets
Gil Blum, Ph.D.
Needham & Co.
Stephen D. Willey
Stifel
Joel Beatty, M.D., C.F.A.
Robert W. Baird & Co
Joseph M. Catanzaro, Ph.D.
Piper Sandler
Kennen MacKay, Ph.D.
RBC Capital Markets
Christopher Liu, Pharm.D.
SBV

Nurix Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Nurix Therapeutics, Inc. 's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Nurix Therapeutics, Inc. or its management. Nurix Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.